“Keeping Up With COVID - One Company's Story”
Harriss Currie
CFO, Treasurer and Senior VP Finance
LUMINEX CORPORATION: FULLY EMBEDDED IN GLOBAL BIOMEDICAL SCIENCE AND HEALTHCARE ENTERPRISES

Actionable solutions across the biomedical spectrum
Luminex is a biotech company providing molecular, proteomic, and cellular analysis tools and tests to life science and diagnostics markets exceeding $12B per year.

We seek to enable labs around the world to quickly advance science and deliver beneficial, cost-effective healthcare solutions.
LUMINEX CORPORATION: WHO WE ARE

ATTRACTIVE MARKETS
- Serving a growing $12B+ global life science marketplace
- Flexibility in reaching customers through direct sales, strategic partnerships, and other channels

DIVERSIFIED SOLUTIONS
- Differentiated platforms and assays, supported by 850+ patents, to address the needs of our clinical, biopharmaceutical, and research customers
- Enabling molecular, proteomic and cellular analysis

FINANCIAL STRENGTH & GLOBAL REACH
- Healthy profitability, increasing quarterly dividend, consistent cash flow and strong balance sheet
- ~25,000 instruments worldwide driving 75% annuity revenue
OUR STORY
WE HELP LABS OBTAIN ANSWERS TO CHALLENGING MEDICAL QUESTIONS BY PROVIDING SOLUTIONS FOR DIAGNOSTIC AND RESEARCH PURPOSES.
DEVELOPING SOLUTIONS DURING THE COVID-19 PANDEMIC

PCR-BASED TESTS

- Two Luminex PCR-based COVID-19 tests have already received EUA clearance
- Run on ARIES and NxTAG Systems
- Expecting EUA clearance on NxTAG RPP+SARS-CoV-2 Assay any day
- ARIES A/B & RSV + SARS-CoV-2 Assay EUA submission is ready to go to FDA
- Planning for EUA submission to FDA for VERIGENE II RSP Flex Assay later this quarter

ANTIBODY-BASED TESTS

- xMAP Multi-Antigen IgG assay has received EUA clearance
- Developing additional antibody tests to help identify individuals who may have some level of immunity to the virus
- Anticipate submitting EUA submission to FDA for xMAP-based Neutralization Assay in Q2 ’21
MULTIPLE COVID-19 SOLUTIONS FOR THE LONG RUN

SHORT/MID-TERM: DIAGNOSTICS AND SEROLOGY HELP FLATTEN THE CURVE

LONG TERM: RESEARCH, THERAPEUTICS AND VACCINES HELP LOWER THE CURVE

ARIES®
- Targeted, sample-to-answer diagnostic testing

VERIGENE®
- Syndromic, sample-to-answer diagnostics and surveillance

MAGPIX®
- Syndromic, high-throughput, cost-effective diagnostic testing
- SARS-CoV-2 serology testing for immunity monitoring, vaccine development

LUMINEX® 200™ FLEXMAP 3D®
- High-throughput, multiplex serology, cytokine & proteomic research

xMAP® INTELLIFLEX
- High-throughput, multiplex serology research
- Vaccine, therapeutic, cytokine & proteomic research

Note:
Figures are total assay and system revenue

Molecular Testing
Serology Testing
Vaccines/Therapeutics/Cell Research
SARS-CoV-2 MDx PROJECTS

**Launched**

- **NxTAG® CoV Extended Panel**
  - **NxTAG® RPP+SARS-CoV-2 (CE-IVD)**

- **NxTAG® RPP + SARS-CoV-2 Panel**

**Submitted**

- **NxTAG® RPP v2 (IVD)**
  - Includes updated Flu and other targets*
  - Submitting for EUA in March

- **ARIES® Flu A/B & RSV + SARS-CoV-2 (EUA)**
  - Uses Taqman for improved MFG
  - Submitting for EUA 2/25

- **ARIES® Flu + SARS-CoV-2 Fast**
  - Tech Feasibility underway for ~60-75 min version

- **VERIGENE® SARS-CoV-2 (EUA)**
  - Pooling claim (5 samples)
  - LoD of 100 copies/ml
  - Submitted in Jan ‘21
  - Reprioritized by FDA

- **VERIGENE® II RSP Flex + SARS-CoV-2 (EUA)**
  - Built on RP Flex panel
  - 3 gene CoV target add to PCR tube 4
  - Finalizing submission package

- **VERIGENE® II RSP Flex + SARS-CoV-2 (RUO)**
  - Launch planned for Q2 ‘21

- **VERIGENE® II RSP Flex + SARS-CoV-2 (CE-IVD)**
  - Launch planned for Q3 ‘21

*** Biosurveillance recommendations**
xMAP® SARS-CoV-2 MULTI-ANTIGEN IgG ASSAY

Example of a bead in the assay

Detects IgG antibodies against 3 SARS-CoV-2 antigens, providing comprehensive results:

• S1 subunit of the spike protein
• Receptor Binding Domain (RBD) of the spike protein
• Nucleocapsid protein
EXPANDED MANUFACTURING TO MEET INCREASED DEMAND

Austin/ARIES®
- 600K test capacity. Beginning of 2020
- 1.6M test capacity. Summer 2020
- 3.2M test capacity (investment of ~$5M). Ready now!
- 4.5M test capacity (investment of $1M). Mid-2021
- 6M+ test capacity (investment of ~$5M). Beginning of 2022
- 50K sq ft facility expansion. Mid-2021

Toronto/NxTAG®
- 1M test capacity. Beginning of 2020
- 9M test capacity (investment of $500K). Summer 2020

Chicago/VERIGENE®
- ~25% increase in footprint ($8M facility purchase). Q1 2021
- 600K test capacity (VERIGENE II fully automated lines)
- 1.2M test capacity (VERIGENE I)
- $3.4M total investment (already paid)

Madison/Reagents
- 10%+ increase in building footprint (investment of $2.5M)
- Supports both ARIES® and VERIGENE II
Questions?